About MindMed
MindMed is a publicly listed company based in New York (United States) founded in 2019 by JR Rahn and Stephen L Hurst. Psychedelic-based therapies for brain health disorders are developed. The company has 74 employees. MindMed has completed 1 acquisition, including HealthMode. Its chief executive, as recorded, is Stephen L Hurst. Its website mindmed.co draws about 15 thousand monthly visits. MindMed offers products and services including MM120 ODT and MM402. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is MIND MEDICINE (MINDMED) INC. Its competitors include QurAlis, Passage Bio and Harmony Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
MindMed was founded in 2019 and is headquartered in New York, United States. Psychedelic-based therapies are developed to address brain health disorders, including generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. Product candidates are advanced through rigorous scientific methods to target unmet patient needs. Research efforts span diverse therapeutic areas and mechanisms of action within the biotechnology sector.
- Net Profit-$183.79 M (USD)-69.12as on Dec 31, 2025
- EBITDA-$166.31 M (USD)-60.86as on Dec 31, 2025
- Latest Funding Round$75M (USD), Post-IPO
Mar 2024
- Investors
- Employee Count74
- Investments & Acquisitions
Products & Services of MindMed
MindMed offers a comprehensive portfolio of products and services, including MM120 ODT and MM402.
Investigational drug targeting Generalized Anxiety Disorder and Major Depressive Disorder.
Drug candidate for Autism Spectrum Disorder symptoms.
Apps and channels of MindMed
its YouTube channel MindMed has 169 subscribers and 2 videos.
Videos from MindMed
The most watched videos on MindMed's YouTube channel, MindMed (169 subscribers). Click a video to play it here.
More on MindMed.
Funding Insights of MindMed
- Total Rounds 9
- Last Round Post-IPO — $75M
- Investors Count 1
All 9 funding rounds of MindMed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $75M | Post-IPO | – | – | – |
| Aug 2023 | $7M | Post-IPO | – | – | – |
| Mar 2021 | $15.4M | Post-IPO | – | – | – |
| Jan 2021 | $499,618 | Post-IPO | – | – | – |
| Dec 2020 | $78,268 | Post-IPO | – | – | – |
| Nov 2020 | $247,705 | Post-IPO | – | – | – |
| Jun 2020 | $468,248 | Post-IPO | – | – | – |
| Mar 2020 | $19.29M | Post-IPO | – | – | – |
| Nov 2019 | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in MindMed
MindMed has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Broadway Mining.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Copper and gold deposits are explored and mined by Broadway. | 2010 | broadwaymining.com | Oakville, Canada |
Investor details for MindMed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MindMed
87 people are tracked at MindMed (41 in leadership, 24 in board & advisors, 22 in team); the tracked headcount is 74.
| Name | Role | Group |
|---|---|---|
JR Rahn | Co-Founder | Leadership |
Stephen L Hurst | Co-Founder & CEO | Leadership |
Robert Barrow | CEO | Leadership |
Schond Greenway | Chief Financial Officer | Leadership |
Stephen Schneider | Senior Director, Drug Substance Development | Leadership |
Carrie Liao | Chief Accounting Officer | Leadership |
Dan Karlin | Chief Medical Officer | Leadership |
Amber Doty | Senior Director, Pharmaceutical Development Project Leadership & Operations | Leadership |
Suzuko Kitazawa | Director Of Finance | Leadership |
Julie Tripp Dabt | Senior Director Of Toxicology | Leadership |
Dustin Melton | Director Of Formulation Development And Manufacturing | Leadership |
Gitanjali Jain | Vice President, Head Of Investor Relations | Leadership |
Daniel R. Karlin | Chief Medical Officer | Leadership |
Derek Louie | Associate Director | Leadership |
Alex Cucerov | Senior Director, Commercial Operations And Business Intelligence | Leadership |
Mark Sullivan | Chief Legal Officer | Leadership |
Keisha Novak | Associate Director, Clinical Development | Leadership |
Miri Halperin Wernli | Executive President | Leadership |
Lysa Triantafillou | Vice President, Quality Assurance | Leadership |
Katie Kelly | Associate Director, TMF Operations Manager | Leadership |
67 more people are available in the full profile.
Complete people profiles for MindMed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MindMed
MindMed is a publicly listed company on the NASDAQ with ticker symbol MNMD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Apr 2021
- Listed onNASDAQ: MNMD
- Listed entityMind Medicine (MindMed) Inc.
- Exchange sectorHealth technology
- ISINCA24477V1058
- Share price$15.02 (+1.01% on the day) · 2026-01-15
- Market capitalisation$1.48B
- EPS (diluted, trailing year)$-1.97
- Volume (last session)2,061,920
- Analyst consensusStrong buy
Financials of MindMed
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$183.8M | -$166.3M | |
| 2024 | -$108.7M | -$103.4M | |
| 2023 | -$95.7M | -$90.7M | |
| 2022 | -$56.8M | -$63.1M | |
| 2021 | -$93.0M | -$90.9M |
Detailed financial statements for MindMed
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MindMed
MindMed has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include HealthMode.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI-based wearable devices for clinical trial data collection are provided. | healthmode.com | San Francisco, United States | 2017 | Feb 2021 | •••• |
Complete acquisition details for MindMed
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of MindMed
5 dated milestones of MindMed across 5 years, from founding to its latest funding, stage changes and deals.
- Founded MindMed is founded.
- Funding First funding round.
- Acquisition Acquires HealthMode.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $75.0M.
Competitors of MindMed
MindMed has 3 listed competitors in our database, 3 of them funded. They include QurAlis, Passage Bio and Harmony Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| quralis.com | 2016 | Cambridge, United States | $155.45M | 38 | Drugs and CSF devices are developed for ALS treatment. | |
| passagebio.com | 2017 | Philadelphia, United States | $225.5M | 58 | Gene therapies for CNS rare diseases are developed. | |
| harmonybiosciences.com | 2017 | Plymouth Meeting, United States | $345M | 246 | Developer of therapeutics for rare neurological diseases |
Detailed competitors of MindMed
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MindMed
The website of MindMed (mindmed.co) receives about 15.4K visits a month.
- Monthly visits15.4K
▼ 21.9% vs previous month
Websites whose visitors overlap most with MindMed. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| promusventures.com | 100% | #3,875,333 | View details | ||
| greenmarketreport.com | 100% | View details |
Top companies in Neurology
3 companies that operate in the same segment as MindMed (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mindmed
Complete news archive for MindMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MindMed
MindMed was founded in 2019.
MindMed is headquartered in New York, United States. It is registered at New York, New York, United States.
Stephen L Hurst is the CEO of MindMed, as recorded in our data. They have also founded this company.
MindMed has 74 employees.
MindMed was founded in 2019 and is headquartered in New York, United States. Psychedelic-based therapies are developed to address brain health disorders, including generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. Product candidates are advanced through rigorous scientific methods to target unmet patient needs. Research efforts span diverse therapeutic areas and mechanisms of action within the biotechnology sector.
MindMed's top competitors include Harmony Biosciences, QurAlis and Passage Bio.
MindMed offers MM120 ODT and MM402.
Yes, MindMed is publicly traded on NASDAQ under the ticker symbol MNMD.
MindMed has made 1 acquisition, including HealthMode.
MindMed has 1 investor. Key investors include Broadway Mining.
MindMed operates through Mind Medicine (Mindmed) Inc..